Document:

Exhibit 10.119

 

NOTE PURCHASE AGREEMENT

 

NOTE PURCHASE AGREEMENT dated as of September 30,
2013 (this "Agreement"), by DR. ERIC ROSENBERG (the "Seller"), and Stephen B. Schott, who address is 3569 East
View Drive, Lafayette, CA 94549 (the "Purchaser"). Each of the Seller and the Purchaser is also herein referred to as
a "Party" and collectively as the "Parties".

 

The Seller is the legal and beneficial owner and holder
in due course of a Convertible Debenture dated June 20, 2013 in the principal amount of U.S. $70,750.00 (the "Debenture")
issued by VG LIFE SCIENCES, INC., formerly known as Viral Genetics, Inc., a Delaware corporation ("VG"). The Seller desires
to sell the Debenture to the Purchaser and the Purchaser desires to purchase the Debenture from Seller, upon the terms, conditions
and provisions set forth in this Agreement.

 

NOW, THEREFORE, in consideration
of these premises and other good and valuable consideration, the receipt and legal adequacy of which is hereby acknowledged by
the parties, the Seller and the Purchaser hereby agree as follows:

 

1.Title to Debenture. (a) The Seller represents
and warrants to the Purchaser that

(i) attached hereto is a
true, correct and complete copy of the Debenture; (ii) the Seller has good and marketable title to the Debenture and is the holder
in due course of the Debenture; (iii) the Seller has not pledged the Debenture or granted any security interest, charge or lien
or other encumbrance in or to the Debenture of any nature whatsoever (the

"Liens").

 

(b)   
The Seller further represents and warrants to the Purchaser that the Seller has not received any payments of principal or
interest on the Debenture from VG and has not released VG from any of its obligations under the Debenture.

 

(c)    
The Seller agrees that the title and ownership to the Debenture will pass to the Purchaser upon the execution and delivery
of this Agreement and the assumption of the obligations of the Purchaser to pay the Purchase Price, whereupon the Purchaser shall
become a holder in due course of the Debenture.

 

2.Purchase Price. The Seller agrees to sell the Debenture
to the Purchaser and the Purchaser

agrees to Purchase the Debenture
by making a single payment to the Seller for the total purchase price of U.S. $70,750.00 (the "Purchase Price").

 

3.Payment of Purchase Price. (a) The Purchaser
will pay the balance of the note to the Seller via check.

 

(b)Upon execution of this Agreement, the Seller
will send the original version of the

Debenture to the Purchaser.

 

 

    	1

    	 

    

 

(d)The
Seller represents and warrants to the Purchaser that the Purchaser is acquiring all of the Seller's right, title and
interest in and to the Debenture free and clear of any and all Liens and all of the Seller's right, title and interest in and
to all claims, actions and rights against VG related to or arising out of the Debenture.

 

4.
VG. The Seller acknowledges and agrees that upon the payment of the Purchase Price as provided for herein, the Seller
will not have any claim against VG arising out of or relating to the Debenture or otherwise.

 

5. Mutual
Representations and Warranties. Each of the Purchaser and the Seller hereby represents and warrants to the other that (a)
it has the full legal capacity, power, ability and authority (corporate or individual, as applicable) to execute and deliver
this Agreement and to perform its obligations hereunder; (b) in the case of the Purchaser only, the execution, delivery and
performance of this Agreement has been duly authorized by it in accordance with all requisite corporate power and authority;
as applicable, (c) this Agreement constitutes its legal, valid and binding obligation, enforceable against it in accordance
with its terms, except as enforceability may be limited by applicable bankruptcy, moratorium, insolvency and other similar
laws affecting the enforcement of creditors' rights generally and that enforcement may be limited by general principles of
equity; (d) its execution, delivery and performance of this Agreement does not violate, contravene or cause a breach of, or
default under, any contract or agreement to which it is a party, or violate any decree, order or judgment to which it is a
party or by which it or its properties or assets are bound or any law or regulation applicable to it; and (e) no consent
from, filing with, or notice to any person or entity is required to be made or obtained by it in connection with its
execution, delivery and performance of this Agreement.

 

6. Expenses. Each
Party shall bear its own costs and expenses incurred in connection with its negotiation, execution and delivery of
this Agreement, including, without limitation, the fees and disbursements of its legal counsel.

 

7. Notices.
Any and all notices, consents, instructions and other communications which are required or permitted to be given hereunder
or made by one Party hereto to the other Party hereto pursuant to this Agreement shall be in writing and given as follows: (a)
by personal delivery; (b) by facsimile; or (c) by overnight delivery by a recognized express courier company at the following
respective addresses or facsimile numbers, set forth below:

 

	If to the SELLER	Eric S. Rosenberg, M.D.	 
	 	23 Robbins Street	 
	 	Milton, MA 02186	 
	 	 	 
	If to Purchaser	Stephen B. Schott	 
	 	3569 East View Drive,	 
	 	Lafayette, CA 94549.	 

 

 

 

    	2

    	 

    

 

or at such other address or facsimile number as either party hereto may designate
by notice to the other Party hereto in accordance with this Section 7. All such notices, consents, demands, instructions and other
communications shall be deemed given (a) on the business day delivered, if delivered, personally, (b) on the business day of the
facsimile transmission if received on a business day between the hours of 9:00 a.m. and 5:00 p.m. (in the time zone of the intended
recipient) or on the next business day if received after that time, in each case with an automatic machine confirmation indicating
the time of receipt; or (c) on the second business day after delivery to the overnight courier service with all costs paid.

 

8. Remedies
Cumulative; Severability. (a) All remedies, rights, and privileges available to a Party under, and in respect of,
this Agreement shall be cumulative, and none of them shall be in limitation of any other remedy, right, whether available at
law, in equity or otherwise. All such rights and remedies may be exercised singly or concurrently.

 

(b) The invalidity,
illegality or unenforceability of any term or provision contained in this Agreement (as determined by a court of competent jurisdiction)
shall not affect the validity, legality or enforceability or any other term or provision hereof or the validity, legality or enforceability
of such term or provision in any other jurisdiction or the validity, legality or enforceability of any other term or provision
of this Agreement. It is the intent of the Parties that this Agreement be enforced to the fullest extent permitted by applicable
law. Accordingly, the Parties agree that a court of competent jurisdiction is hereby authorized to by the Parties to modify any
invalid, illegal or unenforceable term or provision to make it valid, legal and enforceable to the maximum extent permitted by
applicable law.

 

9. Amendment;
Waiver. Any amendment, modification or waiver of any term or provision of this Agreement shall only be effective if
such amendment, modification or waiver is evidenced by an instrument in writing duly executed by each of the Parties hereto.
No waiver by a Party of any term or provision of this Agreement shall be deemed to be a waiver of any preceding or subsequent
breach of the same or similar nature or of any other term or provision of this Agreement. Any waiver shall be limited to the
specific instance for which it is given. Any course of dealing between the Parties shall not be considered an amendment or
modification of this Agreement or a waiver of any term or provision thereof;.

 

10. Governing
Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of
California, without regard or reference to any of its choice of laws or conflicts of laws principles which would require or
permit the application of the laws of another jurisdiction.

 

11. Assignment,
etc. This Agreement may not be assigned by either Party nor may a Party's duties or obligations hereunder be delegated
without the prior written consent of the other Party. This Agreement shall inure to the benefit of, and shall be binding
upon, the Parties, their respective successors (whether by merger or consolidation, recapitalization or other similar
transaction) and their permitted assignees.

 

 

    	3

    	 

    

 

12. Drafting
History. In resolving any dispute or controversy arising out of or relating to this Agreement or in connection with
construing any term or provision in this Agreement, there shall be no presumption made or inference drawn because of the
inclusion of a provision not contained in a prior draft or the deletion of a provision contained in a prior
draft. The Parties acknowledge and agree that this Agreement was negotiated and drafted with each Party being represented by
competent legal counsel of its choice and with each Party having opportunity to participate in the drafting of the
provisions hereof and shall therefore this Agreement shall be construed and interpreted as if drafted jointly by the Parties
and not with any presumption against either of the Parties.

 

13.
Complete Agreement. This Agreement constitutes the entire understanding and agreement of the Parties with respect
to the subject matter hereof, and it supersedes all prior and/or contemporaneous understandings and agreements among the Parties,
whether oral or written, with respect to such subject matter, all of which are merged herein. There are no representations, warranties,
agreements or promises between the Parties with respect to such subject matter, except those which are expressly set forth herein.

 

14.
Headings, Counterparts. The section headings contained in this Agreement are
inserted herein for the purpose of convenience and reference only and they are not to be given any substantive effects
nor shall they be used or have any effect upon the construction or interpretation of arty term or provision hereof. Any reference
to the masculine, feminine or neuter gender shall be a reference to such other gender as if appropriate. References to the singular
shall include the plural and vice versa. This Agreement shall be effective when duly executed counterparts are executed and delivered
by each of the Parties. This Agreement may be executed in multiple counterparts (and may be executed by facsimile, PDF or electronic
signature, which shall constitute a legal and valid signature for purposes hereof), each of which shall constitute an original,
and all of which, when taken together, shall constitute one and the same document. The Parties acknowledge and agree that this
Agreement is effective as of its specified date regardless of the fact that it is being executed by either of the. Parties on
another date (including a later date). Facsimile or PDF counterparts of this Agreement shall be deemed to be considered original
and valid counterparts hereof.

 

IN WITNESS WHEREOF, each of the Seller and the Purchaser has duly executed this Agreement as of
the date first written above.

 

 

Accepted and Agreed:

 

By: /s/ Eris S. Rosenberg M.D.                      

Dr. Eric Rosenberg

 

 

By: /s/ Stephen B. Schott                     

Stephen B. Schott

 

 

 

    	4Exhibit 10.120

 

NEITHER THIS
SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE SECURITIES ACT), AND ACCORDINGLY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THIS DEBENTURE DOES NOT REQUIRE PHYSICAL SURRENDER HEREOF IN ORDER TO EFFECT
A PARTIAL PAYMENT, REDEMPTION, OR CONVERSION HEREOF. ACCORDINGLY, THE OUTSTANDING PRINCIPAL AMOUNT OF THIS DEBENTURE MAY BE
LESS THAN THE PRINCIPAL AMOUNT SHOWN BELOW.

 

VG LIFE SCIENCES INC.

 

RESTATEMENT AND AMENDMENT OF UNSECURED
NOTE 

 

UNSECURED NOTE

 

	Santa Barbara, California	$993,023
	Effective Date: October 1, 2013	 

 

FOR VALUE RECEIVED,
VG Life Sciences Inc., a Delaware corporation formerly known as Viral Genetics, Inc., whose address is 121 Gray Ave., Suite
200, Santa Barbara, CA 93101, (“Borrower”), promises to pay to or to the order of Best Investment Trust.,
a California entity (“Lender”), and its successors and assigns, in lawful money of the United States of
America, Nine Hundred Ninety Three Thousand and Twenty Three ($993,023.00) (the “Principal”), with five (5%)
interest per annum. No additional amounts may be tendered hereunder except as mutually agreed to in writing by Borrower and
Lender. This Note is issued as a restatement and amendment of the Secured Revolving Credit Note dated March 5, 2008 issued by
Borrower to Best Investment Inc. and subsequently assigned to Lender, to which such Note additional amounts have been
tendered and owe.

 

		1)	Payment and Conversion.

 

		(a)	Payment. Borrower shall pay to
                                         Lender the Principal under this Note (the “Note”) on or before December 31,
                                         2018 (the “Maturity Date”). Borrower shall pay all amounts due under this
                                         Note in lawful money of the United States of America and without set-off, deduction,
                                         demand or notice. Subject to the limitation set forth in section 1(b) and Section 5.

 

    	1

    	 

    

 

		(b)	Exchange of Loan Obligation.
                                         All or any portion of the then outstanding principal and accrued interest of the Note
                                         (“Exchanged Amount”), may be exchanged for Units at the election of the Lender
                                         at any time prior to the Maturity Date, as defined in the Note, by Lender giving written
                                         notice to Borrower specifying the date of exchange (the “Exchange Date”)
                                         not less than 30 days nor more than 60 days prior to Exchange Date. In exchange for each
                                         $1 of the Exchanged Amount so exchanged, Lender shall receive a number of Units equal
                                         to the Exchanged Amount divided by the Exchange Price. The Exchange Price shall be equal
                                         to the volume-weighted average closing price of the Borrower’s common stock for
                                         the 20 trading days immediately prior to the Exchange Date as reported on the NASD OTCBB,
                                         Pinksheets, or other market where Borrower’s common stock is then quoted for trading,
                                         provided that in the event no such quoted market exists, the Exchange Price shall be
                                         determined according to an independent appraisal ratified by the disinterested members
                                         of the Borrower’s board of directors. Each Unit is composed of one share of Borrower’s
                                         common stock and one warrant to purchase one share of Borrower’s voting common
                                         stock in the form attached hereto as Exhibit C (“Warrant”). The Warrant Price,
                                         as defined in the Warrant, shall be equal to the Exchange Price multiplied by 1.5. An
                                         election made by the Lender to exchange the Loan Obligation for Units cannot be revoked
                                         by Lender without the written consent of Borrower. Both the Note and the Warrant include
                                         a cashless exercise feature enabling conversion into unregistered shares (“Shares”)
                                         of common stock of VGLS based on the spread between the warrant exercise price and the
                                         then-trading value of the underlying VGLS Shares 

                                         

                                         On an Exchange Date the Lender shall deliver to the Borrower the Notice of Conversion
                                         in the form attached hereto as Annex A and the Borrower shall issue and deliver to the
                                         Lender the Units. Should such Notice of Conversion represent all of the remaining Loan
                                         Obligations, Lender shall deliver to Borrower the Note and all other instruments evidencing
                                         the Loan Obligation to the Borrower marked “paid in full.”

 
 

		(c)	 

An
election made to exchange amounts owed hereunder for Shares cannot be revoked without the written consent of the other party.
The Borrower shall issue and deliver to the Lender the Shares within not more than one (1) business day of receiving notice from
Lender. Should such Notice of Conversion represent all of the remaining obligations due hereunder, Lender shall deliver to Borrower
the original Note marked “paid in full.”
 

		(d)	Mandatory Conversion. Any unpaid Principal due hereunder upon the
Maturity Date shall automatically be exchanged for Shares upon the terms described in Section 1(b) above using the Maturity Date
as the Exchange Date, without requiring the additional consent of either party.

 

		i)	Conversion by Borrower. In addition to the limitations imposed by
Section 1(b)(i) above, Borrower may only exercise their right to effect a Conversion of Principal by Lender if all of the following
are true:

 

	 	a.	the
Shares that Lender would receive are, upon receipt, freely-tradable and may be sold or transferred by Lender without restriction
on resale of any kind;
		b.	the Shares are listed or quoted for trading on the OTCBB, Pinksheets or
an equivalent recognized exchange;

		c.	at
the time of delivery of the Shares, the Borrower is in good standing as a publicly traded entity, meeting all requirements for
providing “current information” or “fully-reporting” status as those terms are used in the securities industry,
and is otherwise in good standing under applicable securities law, exchange rules or similar rules or regulations; and

		d.	No Event of Default exists (as defined below).

 

 

    	2

    	 

    

 

		(e)	Warrant.
                                         Upon payment of all Principal and other amounts that may be owing under this Note, including
                                         mandatory conversion at Maturity Date under Section 1(d) Borrower shall deliver to Lender
                                         the Warrant attached hereto as Schedule C.

 

		2)	Interest. All unpaid principle balances under this Secured Revolving Credit Note shall bear
interest (the “Interest Rate”) at a rate equal to five percent (5%) per annum. Interest shall be computed on
the actual number of days elapsed (including the first day but excluding the last day) on the basis of a three hundred sixty-five
(365) day year. Interest shall be payable on the Maturity Date.

 

		3)	Application of Payments. Payments will be applied first to any costs and expenses (including
reasonable attorneys' fees) incurred by Lender in connection with the collection of amounts owing pursuant to this Note, then to
interest accruing at the Default Rate, and then to reduction of Principal. All payments shall be made to Lender at the specified
address until receipt of notice from Lender to the contrary.

 

		4)	Default Rate. Upon the occurrence of an Event of Default, Lender shall be entitled to receive,
and Borrower shall pay to Lender, interest on the outstanding principal balance and any other advances or charges advanced by Lender
at a per annum rate equal to the lesser of (a) twelve percent (12%), or (b) the maximum interest rate which Borrower may by law
pay (the “Default Rate”). The Default Rate shall be computed from the occurrence of the Event of Default until
the earlier of the date upon which the Event of Default is cured or the date upon which due and owing under this Note are paid
in full. The preceding sentence, however, shall not be construed as an agreement or privilege to extend the date of the any payment
due hereunder, or as a waiver of any other right or remedy accruing to Lender by reason of the occurrence of any Event of Default.

 

		5)	Prepayment. This Note may not be prepaid without the prior written consent of Lender.

 

		6)	Security Interest. This Note is unsecured.

 

		7)	Default. Any one of the following occurrences shall constitute an “Event of Default”
under this Unsecured Revolving Credit Note provided that Lender shall be required to give written notice of same:

 

		(a)	The
failure of Borrower to repay all outstanding Principal on or before the Maturity Date, including, without limitation, the timely
delivery of Shares for a Conversion including, without limitation, mandatory conversion at the Maturity Date under Section 1(d)
hereunder;

 

		(b)	The failure of Borrower to promptly perform any obligation of Borrower under, a breach of, or the
existence of an Event of Default as defined in, this Note or the Settlement Agreement; or

 

    	3

    	 

    

 

		(c)	Borrower
becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due; is adjudicated insolvent or bankrupt;
admits in writing its inability to pay its debts; or shall suffer a custodian, receiver or trustee for it or substantially all
of its property to be appointed and if appointed without its consent, not be discharged within sixty (60) consecutive days; makes
an assignment for the benefit of creditors; or suffers proceedings under any law related to bankruptcy, insolvency, liquidation
or the reorganization, readjustment or the release of debtors to be instituted against it and if contested by it not dismissed
or stayed within sixty (60) consecutive days; if proceedings under any law related to bankruptcy, insolvency, liquidation, or the
reorganization, readjustment or the release of debtors is instituted or commenced by or against Borrower; if any order for relief
is entered relating to any of the foregoing proceedings; if Borrower shall call a meeting of its creditors with a view to arranging
a composition or adjustment of its debts; or if Borrower shall by any act or failure to act indicate its consent to, approval of
or acquiescence in any of the foregoing.

 

		8)	Remedies. Upon the happening and during the continuation of any Event
of Default, (i) Lender may, at its sole option, declare the entire Principal immediately due and payable in full; (ii) interest
shall accrue on all amounts due hereunder at the Default Rate until paid in full or such Event of Default is cured; and (iii) Lender
shall have and may exercise any and all rights and remedies available hereunder, at law and in equity, together with any and all
rights and remedies provided in any related document including the Settlement Agreement. The acceptance of any installment or payment
after the occurrence of an Event of Default or event giving rise to the right of acceleration provided for herein shall not constitute
a waiver of such right of acceleration with respect to such Event of Default or event or any subsequent Event of Default. The remedies
of Lender, as provided herein or in any related document, shall be cumulative and concurrent, and may be pursued singularly, successively
or together, at the sole discretion of Lender, and may be exercised as often as occasion therefore shall arise. Any act, omission
or commission of Lender, including, specifically, any failure to exercise any right, remedy or recourse, shall be released and
be effected only through a written document executed by Lender and then only to the extent specifically recited therein. A waiver
or release with reference to any one event shall not be construed as continuing, as a bar to, or as a waiver or release of, any
subsequent right, remedy or recourse as to a subsequent event.

 

		9)	Collection Costs. If one or more Events of Default (or any event which
with notice or passage of time or both would constitute an Event of Default) hereunder shall occur and continues, Borrower promises
to pay all collection costs, including but not limited to all reasonable attorneys' fees, court costs, and expenses of every kind,
incurred by Lender in connection with such collection or the protection or enforcement of any or all of the security for this Note,
whether or not any lawsuit is filed with respect thereto (including costs and reasonable attorneys’ fees on any appeals or
in any bankruptcy proceedings).

 

 

    	4

    	 

    

		10)	Legal Opinions and Disclosures. Within the scope of applicable securities law and at its
cost and expense, Borrower shall cooperate to the fullest commercially reasonable extent in obtaining, or directing its legal counsel
to deliver, legal opinions as and when requested by Borrower pertaining to (x) the removal of restrictive legends from Shares under
Rule 144 or (y) the deposit or new issuance of Shares by Lender to its brokerage electronically, including such supplemental opinions
as are requested by such brokerage, for any Shares issued as a result of Conversions. All such opinions shall be delivered in not
more than one (1) business day of request by Lender, acting reasonably. In the event Lender is required to obtain such legal opinions
at its own expense, the actual and reasonable cost of same shall be added to the Principal balance of this Note. While this Note
is outstanding, Borrower shall use its commercially reasonable best efforts to meet all requirements for providing “current
information” or “fully-reporting” status as those terms are used in the securities industry, and otherwise remain
in good standing under applicable securities law, exchange rules or similar rules or regulations, and otherwise ensure the continued
tradability of its Shares.

 

		11)	Miscellaneous.

 

		(a)	Successors
                                         and Assigns. This Note inures to the benefit of Lender and its successors or assigns,
                                         and binds Borrower, and its respective permitted successors and assigns, and the words
                                         “Lender” and “Borrower” whenever occurring herein shall be deemed
                                         and construed to include such respective successors and assigns.

  

		(b)	Severability. Any term or provision of this Note that is held by
a court of competent jurisdiction or other authority to be invalid, void or unenforceable in any situation or in any jurisdiction
shall not affect the validity or enforceability of the remaining terms and provisions or the validity or enforceability of the
invalid, void or unenforceable term or provision in any other situation or in any other jurisdiction. If the final judgment of
a court of competent jurisdiction or other authority declares that any term or provision of this Note is invalid, void or unenforceable,
the parties agree that the court making such determination shall have the power to and shall, subject to the discretion of such
court, reduce the scope, duration, area or applicability of the term or provision, to delete specific words or phrases, or to replace
any invalid, void or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest
to expressing the intention of the invalid or unenforceable term or provision.

 

		(c)	Waiver. To
                                         the fullest extent permitted by law, Borrower hereby waives all valuation and appraisement
                                         privileges, presentment and demand for payment, protest, notice of protest and nonpayment,
                                         dishonor and notice of dishonor, bringing of suit, lack of diligence or delays in collection
                                         or enforcement of this Note and notice of the intention to accelerate, the release of
                                         any liable party, the release of any security for the indebtedness evidenced hereby,
                                         and any other indulgence or forbearance, and is and shall be directly and primarily liable
                                         for the amount of all sums owing and to be owed hereon, and agrees that this Note and
                                         any or all payments coming due hereunder may be extended or renewed from time to time
                                         without in any way affecting or diminishing Borrower's liability hereunder.

 

 

    	5

    	 

    

		(d)	Notices. All notices required to be given to any of the parties hereunder
shall be in writing and shall be delivered (a) by personal delivery, with receipt acknowledged; (b) by telecopier or electronic
mail (with original copy to follow as set forth herein); (c) by reputable overnight commercial courier service; or (d) by United
States registered or certified mail, return receipt requested, postage prepaid, to the parties at the addresses as set forth below
(subject to the right of a party to designate a different address for itself by notice similarly given). Whenever the giving of
notice is required, the giving of such notice may be waived in writing by the party entitled to receive such notice.

 

If to Borrower:

VG Life Sciences Inc.

121 Gray Ave., Suite 200

Santa Barbara, CA 93101

Attn:President & CEO Fax: (805)-879-9006

Email: jtynan@vglifesciences.com

 

If to Lender:

Best Investment Trust

P.O. Box 1020

South Pasadena, CA 91031

Fax: (818)913-0012

Email: Keledjian@msn.com
or VFS1020@Gmail.com

 

		(e)	Entire Agreement. This Note (together with the Settlement Agreement) contains the entire
agreement between the parties with respect to the subject matter hereof and thereof.

 

		(f)	Modification of Agreement. This Note may not be modified, altered or amended, except by an agreement in writing signed
by both Borrower and Lender.

 

		(g)	Releases by Borrower. Borrower hereby releases Lender from all technical and procedural
errors, defects and imperfections whatsoever in enforcing the remedies available to Lender upon a default by Borrower hereunder.

 

		(h)	Remedies Not Exclusive. No remedy herein conferred upon or reserved to Lender is intended
to be exclusive of any other remedy or remedies available to Lender under this Unsecured Revolving Credit Note, at law, in equity
or by statute, and each and every such remedy shall be cumulative and in addition to every other remedy given hereunder or now
or hereafter existing at law, in equity or by statute.

 

		(i)	Governing Law. This Note shall be governed by and construed under the laws of the State
of California without giving effect to the choice of law provisions thereof.

 

		(j)	Consent to Jurisdiction. Borrower hereby consents that any action or proceeding against
it may be commenced and maintained in any Federal or state court sitting in Los Angeles County, California, and that such courts
shall have jurisdiction with respect to the subject matter hereof and the person of Borrower and the collateral securing Borrower’s
obligations hereunder.

 

 

    	6

    	 

    

		(k)	Time of Essence. Time is of the essence of this Note and all of the obligations hereunder.

 

		(l)	Headings. The headings of the sections of this Note are inserted for convenience only
and do not constitute a part of this Note.

 

		(m)	Waiver of Jury Trial. BORROWER AND LENDER, TO THE FULL EXTENT PERMITTED
BY LAW, EACH HEREBY KNOWINGLY, INTENTIONALLY AND VOLUNTARILY WAIVES, RELINQUISHES AND FOREVER FORGOES HEREBY THE RIGHT TO A TRIAL
BY JURY IN ANY ACTION OR PROCEEDING, INCLUDING, WITHOUT LIMITATION, ANY TORT ACTION, BROUGHT BY EITHER OF THEM AGAINST THE OTHER
BASED UPON, ARISING OUT OF, OR IN ANY WAY RELATING TO OR IN CONNECTION WITH THIS UNSECURED REVOLVING CREDIT NOTE, OR ANY COURSE
OF CONDUCT, ACT, OMISSION, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF ANY PERSON (INCLUDING, WITHOUT
LIMITATION, SUCH PERSON’S DIRECTORS, OFFICERS, PARTNERS, MEMBERS, EMPLOYEES, AGENTS OR ATTORNEYS, OR ANY OTHER PERSONS AFFILIATED
WITH SUCH PERSON), IN CONNECTION WITH THIS NOTE , INCLUDING, WITHOUT LIMITATION, IN ANY COUNTERCLAIM WHICH BORROWER MAY BE PERMITTED
TO ASSERT HEREUNDER OR WHICH MAY BE ASSERTED BY LENDER OR ITS AGENTS AGAINST BORROWER, WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE.
THIS WAIVER BY BORROWER OF ITS RIGHT TO A JURY TRIAL IS A MATERIAL INDUCEMENT FOR LENDER UNDER THIS UNSECURED REVOLVING CREDIT
NOTE.

 

		(n)	Note for Business or Commercial Purpose. BORROWER EXPRESSLY WARRANTS
AND REPRESENTS TO LENDER THAT THIS NOTE IS INTENDED FOR AND WILL BE USED FOR A BUSINESS OR COMMERCIAL PURPOSE AND THAT THIS NOTE
IS NOT INTENDED FOR A CONSUMER, PERSONAL, FAMILY OR HOUSEHOLD PURPOSE.

 

		(o)	Authority. Borrower (and the undersigned representative of Borrower,
if any) represents and warrants that it has full power and authority to execute and deliver this Note, and the execution and delivery
of this Note has been duly authorized and does not conflict with or constitute a default under any law, judicial order or other
agreement affecting Borrower.

 

		(p)	Assignment. Lender may assign, transfer, pledge or hypothecate any or all of this Note or the Shares acquirable upon
exchange without Borrower’s consent.

 

 

    	7

    	 

    

 

IN WITNESS WHEREOF, Borrower has
executed and delivered this Note effective as of the date first above written.

 

BORROWER:

 

VG LIFE SCIENCES INC.

 

 

 

By:
   /s/ John P. Tynan                            

John Tynan, President and CEO

 

 

 

    	8

    	 

    

EXHIBIT A

 

 

NOTICE OF CONVERSION

AT THE ELECTION OF HOLDER

 

(To be Executed by the Registered Holder in order to Convert
the Note)

 

The undersigned hereby irrevocably elects
to convert the above Note into shares of Common Stock, no par value per share (the “Common Stock”), of VG Life Sciences,
Inc. (the “Company”) according to the conditions hereof, as of the date written below. If shares are to be issued in
the name of a person other than undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering
herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged
to the Holder for any conversion, except for such transfer taxes, if any.

 

 

 

	Conversion calculations:	 
	 	Date to Effect Conversion
	 	 
	 	 
	 	Principal Amount of Notes to be Converted
	 	 
	 	 
	 	Applicable Conversion Price
	 	 
	 	 
	 	Signature
	 	 
	 	 
	 	Name:
	 	 
	 	 
	 	Address:

 

 

    	9

    	 

    

 

EXHIBIT B NOTICE OF

 

CONVERSION

 

The undersigned
hereby elects to convert principal of the Note pursuant to Section 1(b) therein into shares of common stock, par value $0.0001
per share, of VG Life Sciences Inc., a Delaware corporation (“Shares”), according to the conditions hereof, as of the
date written below. If Shares are to be issued in the name of a person other than the Lender of the Note, such person will pay
all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested
by the Borrower in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes,
if any.

 

Conversion calculations:

 

Date to Effect Conversion:

 

Principal Amount of Note to be Converted:

 

Number
of shares of Common Stock to be issued:

 

 

 

Signature: Name: Address:

 

 

    	10

    	 

    

EXHIBIT C – WARRANT 

 

VG LIFE SCIENCES INC.

 

Warrant for the Purchase
of

Shares of Common Stock

Par Value $0.0001

 

 

WARRANT AGREEMENT

 

 

THE HOLDER OF THIS WARRANT, BY ACCEPTANCE
HEREOF, BOTH WITH RESPECT TO THE WARRANT AND COMMON STOCK ISSUABLE UPON EXERCISE OF THE WARRANT, AGREES AND ACKNOWLEDGES THAT THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE TRANSFERRED
OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR OTHER COMPLIANCE UNDER THE SECURITIES ACT OR THE LAWS OF THE APPLICABLE
STATE OR A “NO ACTION” OR INTERPRETIVE LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE ISSUER, AND ITS COUNSEL, TO THE EFFECT THAT THE SALE OR TRANSFER IS EXEMPT FROM REGISTRATION UNDER
THE SECURITIES ACT AND SUCH STATE STATUTES.

 

Pursuant to the
payment in full of the Restated and Amended Note dated October 1, 2013 by and between the Company and Holder (the
“Note”), this is to certify that, for value received, Best Investment Trust (the “Holder”) is
entitled to purchase from VG Life Sciences Inc. a Delaware corporation (the “Company”), on the terms and
conditions hereinafter set forth, one and one-half share of common stock per one common share received through conversion
(“Warrant Shares”) at the conversion price (“Warrant Price”) of the Company’s common stock, par
value $0.0001 (the “Common Stock”). Upon exercise of this warrant in whole or in part, a certificate for the
Warrant Shares so purchased shall be issued and delivered to the Holder. The Warrant include a cashless exercise feature
enabling conversion into unregistered shares (“Shares”) of common stock of VGLS based on the spread between the
warrant exercise price and the then-trading value of the underlying VGLS Shares If less than the total warrant is exercised,
a new warrant of similar tenor shall be issued for the unexercised portion of this warrant. By acceptance hereof, the Holder
agrees to be bound by the terms and conditions of this warrant.

 

This warrant is granted subject to the following further terms
and conditions:

 

 

    	11

    	 

    

		1.	This warrant shall vest and be exercisable immediately, and shall expire at 5:00 pm Pacific Time
on the five-year anniversary date of the date on which this warrant is issued. In order to exercise this warrant with respect to
all or any part of the Warrant Shares for which this warrant is at the time exercisable, Holder must take the following actions:

 

	 	(a)	Deliver to the Corporate Secretary of the Corporation an executed notice of exercise in substantially the form of notice attached to this Agreement (the “Exercise Notice”) in which there is specified the number of Warrant Shares that are to be purchased under the exercised warrant.

 

		(b)	Pay the aggregate Warrant Price for the purchased shares through full payment in cash or by check
made payable to the Corporation’s order or give notice of exercising of a cashless exercise feature enabling conversion into
unregistered shares (“Shares”) of common stock of VGLS based on the spread between the warrant exercise price and the
then-trading value of the underlying VGLS Shares

 

	 	(c)	Furnish to the Corporation appropriate documentation that the person or persons exercising the warrant (if other than Holder) have the right to exercise this warrant.
	 	 	 
	 	(d)	For purposes of this Agreement, the Exercise Date shall be the date on which the executed Exercise Notice shall have been delivered to the Company. Except to the extent the sale and remittance procedure specified above is utilized in connection with the warrant exercise, payment of the Warrant Price for the purchased shares must accompany such Exercise Notice.
	 	 	 
	 	(e)	Upon such exercise, the Company shall issue and cause to be delivered with all reasonable dispatch (and in any event within three business days of such exercise) to or upon the written order of the Holder at its address, and in the name of the Holder, a certificate or certificates for the number of full Warrant Shares issuable upon the exercise together with such other property (including cash) and securities as may then be deliverable upon such exercise. Such certificate or certificates shall be deemed to have been issued and the Holder shall be deemed to have become a holder of record of such Warrant Shares as of the Exercise Date.

 

2.           The Warrant
Shares have not and may not be registered as of the date of exercise of this warrant under the Securities Act or the securities
laws of any state. This warrant and the Warrant Shares issuable on exercise of the warrant, when and if issued, are and may be
“restricted securities” as defined in Rule 144 promulgated by the Securities and Exchange Commission and must be held
indefinitely unless subsequently registered under the Securities Act and any other applicable state registration requirements,
or an exemption from such registration requirements for resale is available. The Company is under no obligation to register the
securities under the Securities Act or under applicable state statutes. In the absence of such a registration or an available exemption
from registration, sale of the Warrant Shares will be prohibited. The Holder shall confirm to the Company the representations set
forth above in connection with the exercise of all or any portion of this warrant.

 

 

    	12

    	 

    

 

3.             The Company,
during the term of this Agreement, will obtain from the appropriate regulatory agencies any requisite authorization in order to
issue and sell such number of shares of its Common Stock as shall be sufficient to satisfy the requirements of the Agreement.

 

4.             The number of
Warrant Shares purchasable upon the exercise of this warrant and the Warrant Price per share shall be subject to adjustment from
time to time subject to the following terms. If the outstanding shares of Common Stock of the Company are increased, decreased,
changed into or exchanged for a different number or kind of shares of the Company through reorganization, recapitalization, reclassification,
stock dividend, stock split or reverse stock split, the Company or its successors and assigns shall make an appropriate and proportionate
adjustment in the number or kind of shares, and the per-share Warrant Price thereof, which may be issued to the Holder under this
Agreement upon exercise of the warrants granted under this Agreement. The purchase rights represented by this warrant shall not
be exercisable with respect to a fraction of a share of Common Stock. Any fractional shares of Common Stock arising from the dilution
or other adjustment in the number of shares subject to this warrant shall be rounded up to the nearest whole share.

 

5.             The Company
covenants and agrees that all Warrant Shares which may be delivered upon the exercise of this warrant will, upon delivery, be free
from all taxes, liens, and charges with respect to the purchase thereof; provided, that the Company shall have no obligation with
respect to any income tax liability of the Holder.

 

6.             The Company
agrees at all times to reserve or hold available a sufficient number of shares of Common Stock to cover the number of Warrant Shares
issuable upon the exercise of this and all other warrants of like tenor and other convertible securities then outstanding.

 

7.             This warrant
shall not entitle the Holder hereof to any voting rights or other rights as a shareholder of the Company, or to any other rights
whatsoever, except the rights herein expressed, and no dividends shall be payable or accrue in respect of this warrant or the interest
represented hereby or the Warrant Shares purchasable hereunder until or unless, and except to the extent that, this warrant shall
be exercised.

 

8.              The Company
may deem and treat the registered owner of this warrant as the absolute owner hereof for all purposes and shall not be affected
by any notice to the contrary.

 

9.              In the event
that any provision of this Agreement is found to be invalid or otherwise unenforceable under any applicable law, such invalidity
or unenforceability shall not be construed as rendering any other provisions contained herein invalid or unenforceable, and all
such other provisions shall be given full force and effect to the same extent as though the invalid or unenforceable provision
were not contained herein.

 

10.            This Agreement
shall be governed by and construed in accordance with the internal laws of the state of California without regard to the principles
of conflicts of law thereof.

 

 

    	13

    	 

    

11.            In
case this warrant shall be mutilated, lost, stolen, or destroyed, the Company may at its discretion issue and deliver in exchange
and substitution for and on cancellation of the mutilated warrant, or in lieu of and substitution for the warrant lost, stolen,
or destroyed, a new warrant of like tenor and representing an equivalent right or interest; but only on receipt of evidence satisfactory
to the Company of such loss, theft, or destruction of this warrant and indemnity satisfactory to the Company. The Holder shall
also comply with such other reasonable regulations and pay such other reasonable charges as the Company may prescribe.

 

12.            This
Agreement shall be binding on and inure to the benefit of the Company and the person to whom a warrant is granted hereunder, and
such person’s heirs, executors, administrators, legatees, personal representatives, assignees, and transferees.

 

13.            The
right to exercise this Warrant shall be subject to the beneficial ownership limitations of Section 1(d)(i) of the Note including
the right of Holder to waive such limitations as specified therein.

 

IN WITNESS
WHEREOF, the Company has caused this warrant to be executed by the signature of its duly authorized officer, effective the 1st
day of October 2013.

 

VG LIFE SCIENCES INC.

 

 

 

By:    /s/ John P. Tynan               

Duly Authorized Officer

John P. Tynan

 

 

 

    	14

    	 

    

 

Exercise Notice

(to be signed only
upon exercise of warrant)

 

TO:         VG LIFE SCIENCES INC.

 

The Holder of the attached
warrant hereby irrevocable elects to exercise the purchase rights represented by the warrant for, and to purchase thereunder, _________________
shares of common stock of VG Life Sciences Inc. and herewith makes payment therefor, and requests that the certificate(s) for such
shares be delivered to the Holder at:

 

 

 

 

 

 

 

If acquired without registration under
the Securities Act of 1933, as amended (“Securities Act”), the Holder represents that the Common Stock is being acquired
without a view to, or for, resale in connection with any distribution thereof without registration or other compliance under the
Securities Act and applicable state statutes, and that the Holder has no direct or indirect participation in any such undertaking
or in the underwriting of such an undertaking. The Holder understands that the Common Stock has not been registered, but is being
acquired by reason of a specific exemption under the Securities Act as well as under certain state statutes for transactions by
an issuer not involving any public offering and that any disposition of the Common Stock may, under certain circumstances, be
inconsistent with these exemptions. The Holder acknowledges that the Common Stock must be held and may not be sold, transferred,
or otherwise disposed of for value unless subsequently registered under the Securities Act or an exemption from such registration
is available. The Company is under no obligation to register the Common Stock under the Securities Act, except as provided in
the Agreement for the warrant. The certificates representing the Common Stock will bear a legend restricting transfer, except
in compliance with applicable federal and state securities statutes.

 

The Holder
agrees and acknowledges that this purported exercise of the warrant is conditioned on, and subject to, any compliance with requirements
of applicable federal and state securities laws deemed necessary by the Company.

 

DATED this         day
of                                    ,
       .

 

 

 

 

                                                                                       

Signature

 

 

    	15

    	 

    

 

Transfer Form

 

FOR VALUE RECEIVED,                                                                                               

 

hereby sell, assign, and transfer unto

 

 

 

 

 

 

 

warrants to purchase shares of the Common Stock of VG Life
Sciences Inc., represented by the within instrument, and do hereby irrevocably constitute and appoint:

 

 

 

to transfer said warrants stock on the books of the
within named Corporation with full power of substitution in the premises.

 

Dated                                                                ,
            .

 

 

 

                                                                                         

Signature

 

 

 

In presence of

 

                                                                                         

 

 

 

    	16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]